Litcius/Paper detail

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

Chen Li, Long Wan, Jie Luo, Mingyan Jiang, Keke Wang

2021International Journal of Nanomedicine22 citationsDOIOpen Access PDF

Abstract

Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.

Topics & Concepts

Diabetes mellitusMedicineDrug deliveryIntensive care medicineBiomedical engineeringMaterials scienceNanotechnologyEndocrinologyPancreatic function and diabetesAdvanced Drug Delivery Systems3D Printing in Biomedical Research
Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment | Litcius